GILD · News · 20261030N
Guidance and Outlook
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 67 · Surprise 76 · In source text
CFO Andrew Dickinson raised 2026 product-sales guidance to $31.0 billion–$31.3 billion. The range includes base-business sales guidance of $30.7 billion–$31.0 billion, whose midpoint was raised by $900 million from August. Management expects HIV revenue to grow approximately 12% in 2026, supported by Biktarvy, Descovy and Yeztugo.
Key facts
- Gilead raised 2026 product sales guidance to $31 billion-$31.3 billion, including base business sales of $30.7 billion-$31 billion; the base business midpoint was raised by $900 million from August. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +9.2% | Gilead raised 2026 product sales guidance to $31 billion-$31.3 billion, including base business sales of $30.7 billion-$31 billion; the… |